CR20140187A - Compuestos de piperazina alquilados como inhibidores de la actividad btk - Google Patents
Compuestos de piperazina alquilados como inhibidores de la actividad btkInfo
- Publication number
- CR20140187A CR20140187A CR20140187A CR20140187A CR20140187A CR 20140187 A CR20140187 A CR 20140187A CR 20140187 A CR20140187 A CR 20140187A CR 20140187 A CR20140187 A CR 20140187A CR 20140187 A CR20140187 A CR 20140187A
- Authority
- CR
- Costa Rica
- Prior art keywords
- compounts
- rented
- piperazine
- inhibitors
- btk activity
- Prior art date
Links
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 title 2
- 239000003112 inhibitor Substances 0.000 title 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 150000004885 piperazines Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Se proporcionan los compuestos de piperazina alquilados de la Fórmula I incluyendo sus estereoisómeros, tautómeros y sales farmacéuticamente aceptables, útiles para inhibir Btk cinasa y para tratar trastornos inmunes tales como la inflamación mediada por
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161555395P | 2011-11-03 | 2011-11-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20140187A true CR20140187A (es) | 2014-06-20 |
Family
ID=47146780
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20140187A CR20140187A (es) | 2011-11-03 | 2014-04-24 | Compuestos de piperazina alquilados como inhibidores de la actividad btk |
Country Status (22)
Country | Link |
---|---|
US (3) | US8729072B2 (es) |
EP (1) | EP2773639B1 (es) |
JP (2) | JP5976828B2 (es) |
KR (1) | KR101716011B1 (es) |
CN (1) | CN104024255B (es) |
AR (1) | AR088642A1 (es) |
AU (1) | AU2012332368A1 (es) |
BR (1) | BR112014010439A2 (es) |
CA (1) | CA2853970A1 (es) |
CL (1) | CL2014001158A1 (es) |
CO (1) | CO6950475A2 (es) |
CR (1) | CR20140187A (es) |
EA (1) | EA027561B1 (es) |
IL (1) | IL232280A0 (es) |
IN (1) | IN2014CN03265A (es) |
MA (1) | MA35725B1 (es) |
MX (1) | MX2014005289A (es) |
PE (1) | PE20141686A1 (es) |
SG (1) | SG11201401993RA (es) |
TW (1) | TW201326171A (es) |
WO (1) | WO2013067277A1 (es) |
ZA (1) | ZA201403158B (es) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013021374A2 (en) | 2011-08-05 | 2013-02-14 | Mitraltech Ltd. | Techniques for percutaneous mitral valve replacement and sealing |
UA111756C2 (uk) * | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
CA2853970A1 (en) * | 2011-11-03 | 2013-05-10 | F. Hoffmann-La Roche Ag | Alkylated piperazine compounds as inhibitors of btk activity |
CN105358545A (zh) | 2013-07-03 | 2016-02-24 | 豪夫迈·罗氏有限公司 | 杂芳基吡啶酮和氮杂-吡啶酮酰胺化合物 |
KR101813830B1 (ko) | 2013-12-05 | 2017-12-29 | 에프. 호프만-라 로슈 아게 | 친전자성 작용기를 갖는 헤테로아릴 피리돈 및 아자-피리돈 화합물 |
CA2932351A1 (en) | 2013-12-13 | 2015-06-18 | Dana-Farber Cancer Institute, Inc. | Methods to treat lymphoplasmacytic lymphoma |
US9908872B2 (en) | 2013-12-13 | 2018-03-06 | Dana-Farber Cancer Institute, Inc. | Methods to treat lymphoplasmacytic lymphoma |
WO2015151006A1 (en) | 2014-03-29 | 2015-10-08 | Lupin Limited | Substituted purine compounds as btk inhibitors |
CA2946538A1 (en) | 2014-04-04 | 2015-10-08 | Del Mar Pharmaceuticals | Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer |
WO2015170266A1 (en) | 2014-05-07 | 2015-11-12 | Lupin Limited | Substituted pyrimidine compounds as btk inhibitors |
JP6507234B2 (ja) * | 2014-10-02 | 2019-04-24 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | ブルトンチロシンキナーゼ(btk)によって介入される障害の処置における使用のためのピラゾールカルボキサミド化合物 |
WO2016065138A1 (en) | 2014-10-22 | 2016-04-28 | Dana-Farber Cancer Institute, Inc. | Thiazolyl-containing compounds for treating proliferative diseases |
CN107108604B (zh) | 2014-10-27 | 2020-07-24 | 豪夫迈·罗氏有限公司 | 制备三环内酰胺化合物的方法 |
CN105837576B (zh) | 2015-01-14 | 2019-03-26 | 湖北生物医药产业技术研究院有限公司 | Btk抑制剂 |
HRP20220258T1 (hr) * | 2015-03-10 | 2022-04-29 | Aurigene Discovery Technologies Limited | Sastavi 1,2,4-oksadiazola i tiadiazola kao imunomodulatora |
CA2997859A1 (en) | 2016-02-29 | 2017-09-08 | F. Hoffmann-La Roche Ag | Dosage form compositions comprising an inhibitor of bruton's tyrosine kinase |
MA46995A (fr) | 2016-12-03 | 2019-10-09 | Acerta Pharma Bv | Méthodes et compositions pour l'utilisation de lymphocytes t thérapeutiques en association avec des inhibiteurs de kinase |
MX2020012097A (es) * | 2016-12-15 | 2021-10-06 | Hoffmann La Roche | Proceso para preparar inhibidores de tirosina cinasa de bruton (btk). |
CN107445981B (zh) * | 2017-08-25 | 2018-06-22 | 牡丹江医学院 | 一种用于防治***的活性化合物 |
JP2022522153A (ja) | 2019-02-25 | 2022-04-14 | グアンジョウ・ルペン・ファーマシューティカル・カンパニー・リミテッド | Btkおよびその変異体の阻害剤 |
EA202192575A1 (ru) | 2019-03-21 | 2022-01-14 | Онксео | Соединения dbait в сочетании с ингибиторами киназ для лечения рака |
WO2021066958A1 (en) | 2019-10-05 | 2021-04-08 | Newave Pharmaceutical Inc. | Inhibitor of btk and mutants thereof |
US20220401436A1 (en) | 2019-11-08 | 2022-12-22 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
WO2021164735A1 (en) | 2020-02-20 | 2021-08-26 | Hutchison Medipharma Limited | Heteroaryl heterocyclic compounds and uses thereof |
US20230348471A1 (en) * | 2020-06-18 | 2023-11-02 | Shanghai Synergy Pharmaceutical Sciences Co., Ltd. | Bruton's tyrosine kinase inhibitor and preparation method therefor |
KR20230104125A (ko) | 2020-09-21 | 2023-07-07 | 허치슨 메디파르마 리미티드 | 헤테로아릴 헤테로사이클릭 화합물 및 이의 용도 |
WO2022094172A2 (en) | 2020-10-30 | 2022-05-05 | Newave Pharmaceutical Inc. | Inhibitors of btk |
EP4263552A1 (en) | 2020-12-20 | 2023-10-25 | Guangzhou Lupeng Pharmaceutical Company Ltd. | Btk degrader |
WO2023143491A1 (zh) * | 2022-01-28 | 2023-08-03 | 和记黄埔医药(上海)有限公司 | 7,8-二氢-2h-环戊二烯并吡咯并吡嗪酮化合物的合成方法 |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US5583024A (en) | 1985-12-02 | 1996-12-10 | The Regents Of The University Of California | Recombinant expression of Coleoptera luciferase |
US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
JPH08336393A (ja) | 1995-04-13 | 1996-12-24 | Mitsubishi Chem Corp | 光学活性なγ−置換−β−ヒドロキシ酪酸エステルの製造法 |
US6602677B1 (en) | 1997-09-19 | 2003-08-05 | Promega Corporation | Thermostable luciferases and methods of production |
CA2453113A1 (en) | 2001-07-12 | 2003-01-23 | Avecia Limited | Microencapsulated catalyst, methods of preparation and methods of use thereof |
US7405295B2 (en) | 2003-06-04 | 2008-07-29 | Cgi Pharmaceuticals, Inc. | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds |
US7393848B2 (en) | 2003-06-30 | 2008-07-01 | Cgi Pharmaceuticals, Inc. | Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds |
US20060178367A1 (en) | 2004-11-10 | 2006-08-10 | Currie Kevin S | Certain imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof |
CA2601628C (en) | 2005-03-10 | 2014-05-13 | Cgi Pharmaceuticals, Inc. | Certain substituted amides, method of making, and method of use thereof |
CA3052368A1 (en) | 2005-10-07 | 2007-04-19 | Exelixis, Inc. | Azetidines as mek inhibitors |
US7838523B2 (en) | 2006-09-11 | 2010-11-23 | Cgi Pharmaceuticals, Inc. | Certain substituted amides, method of making, and method of use thereof |
AR063706A1 (es) | 2006-09-11 | 2009-02-11 | Cgi Pharmaceuticals Inc | Determinadas amidas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden. |
AR063946A1 (es) | 2006-09-11 | 2009-03-04 | Cgi Pharmaceuticals Inc | Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden. |
CL2008002793A1 (es) * | 2007-09-20 | 2009-09-04 | Cgi Pharmaceuticals Inc | Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras |
US8426441B2 (en) | 2007-12-14 | 2013-04-23 | Roche Palo Alto Llc | Inhibitors of bruton's tyrosine kinase |
US7683064B2 (en) | 2008-02-05 | 2010-03-23 | Roche Palo Alto Llc | Inhibitors of Bruton's tyrosine kinase |
US8426424B2 (en) | 2008-05-06 | 2013-04-23 | Cgi Pharmaceuticals, Inc. | Certain substituted amides, method of making, and method of use thereof |
EP2297142B1 (en) | 2008-06-24 | 2015-10-14 | F. Hoffmann-La Roche AG | Novel substituted pyridin-2-ones and pyridazin-3-ones |
PT2300459E (pt) * | 2008-07-02 | 2013-07-04 | Hoffmann La Roche | Novas fenilpirazinonas utilizadas como inibidores de cinase |
CN102066370B (zh) | 2008-07-15 | 2014-05-14 | 霍夫曼-拉罗奇有限公司 | 苯基-咪唑并吡啶类和哒嗪类 |
WO2010056875A1 (en) | 2008-11-12 | 2010-05-20 | Cgi Pharmaceuticals, Inc. | Pyridazinones and their use as btk inhibitors |
US8299077B2 (en) * | 2009-03-02 | 2012-10-30 | Roche Palo Alto Llc | Inhibitors of Bruton's tyrosine kinase |
CA2748414A1 (en) | 2009-04-24 | 2010-10-28 | F. Hoffmann-La Roche Ag | Inhibitors of bruton's tyrosine kinase |
EP2424368B1 (en) | 2009-04-29 | 2014-12-31 | Locus Pharmaceuticals, Inc. | Pyrrolotriazine compounds |
AR078320A1 (es) * | 2009-09-04 | 2011-11-02 | Biogen Idec Inc | Derivados nitrogenados heterociclicos inhibidores de tirosinquinasas de bruton(btk), formulaciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades autoinmunes, inflamatorias y canceres. |
CA2798634C (en) * | 2010-05-07 | 2019-04-16 | Gilead Connecticut, Inc. | Pyridone and aza-pyridone compounds and methods of use |
AR082590A1 (es) | 2010-08-12 | 2012-12-19 | Hoffmann La Roche | Inhibidores de la tirosina-quinasa de bruton |
BR112013007506A2 (pt) | 2010-09-01 | 2016-07-12 | Genentech Inc | piridinonas/pirazinonas - métodos de criação e de uso |
CN103201277B (zh) | 2010-09-01 | 2015-11-25 | 吉利德康涅狄格有限公司 | 哒嗪酮、其制备方法及使用方法 |
MX345170B (es) | 2011-05-17 | 2017-01-19 | Hoffmann La Roche | Inhibidores de la tirosina-cinasa de bruton. |
EP2744804B1 (en) | 2011-08-17 | 2017-05-17 | F. Hoffmann-La Roche AG | Inhibitors of bruton's tyrosine kinase |
UA111756C2 (uk) * | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
CA2853970A1 (en) * | 2011-11-03 | 2013-05-10 | F. Hoffmann-La Roche Ag | Alkylated piperazine compounds as inhibitors of btk activity |
-
2012
- 2012-11-02 CA CA2853970A patent/CA2853970A1/en not_active Abandoned
- 2012-11-02 US US13/667,114 patent/US8729072B2/en active Active
- 2012-11-02 JP JP2014541115A patent/JP5976828B2/ja not_active Expired - Fee Related
- 2012-11-02 MX MX2014005289A patent/MX2014005289A/es active IP Right Grant
- 2012-11-02 WO PCT/US2012/063198 patent/WO2013067277A1/en active Application Filing
- 2012-11-02 TW TW101140859A patent/TW201326171A/zh unknown
- 2012-11-02 PE PE2014000639A patent/PE20141686A1/es not_active Application Discontinuation
- 2012-11-02 AR ARP120104129A patent/AR088642A1/es unknown
- 2012-11-02 KR KR1020147014782A patent/KR101716011B1/ko active IP Right Grant
- 2012-11-02 IN IN3265CHN2014 patent/IN2014CN03265A/en unknown
- 2012-11-02 CN CN201280065838.8A patent/CN104024255B/zh not_active Expired - Fee Related
- 2012-11-02 SG SG11201401993RA patent/SG11201401993RA/en unknown
- 2012-11-02 EP EP12783838.1A patent/EP2773639B1/en not_active Not-in-force
- 2012-11-02 AU AU2012332368A patent/AU2012332368A1/en not_active Abandoned
- 2012-11-02 EA EA201490859A patent/EA027561B1/ru not_active IP Right Cessation
- 2012-11-02 BR BR112014010439A patent/BR112014010439A2/pt not_active Application Discontinuation
-
2014
- 2014-04-07 US US14/246,471 patent/US8946213B2/en active Active
- 2014-04-24 CR CR20140187A patent/CR20140187A/es unknown
- 2014-04-28 IL IL232280A patent/IL232280A0/en unknown
- 2014-04-30 CO CO14093206A patent/CO6950475A2/es active IP Right Grant
- 2014-04-30 ZA ZA2014/03158A patent/ZA201403158B/en unknown
- 2014-05-02 CL CL2014001158A patent/CL2014001158A1/es unknown
- 2014-06-06 MA MA37107A patent/MA35725B1/fr unknown
- 2014-12-11 US US14/566,920 patent/US9115152B2/en active Active
-
2015
- 2015-08-24 JP JP2015165095A patent/JP2016028045A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
EA201490859A1 (ru) | 2014-09-30 |
SG11201401993RA (en) | 2014-05-29 |
US8946213B2 (en) | 2015-02-03 |
CO6950475A2 (es) | 2014-05-20 |
JP2014532763A (ja) | 2014-12-08 |
EA027561B1 (ru) | 2017-08-31 |
MA35725B1 (fr) | 2014-12-01 |
PE20141686A1 (es) | 2014-11-08 |
BR112014010439A2 (pt) | 2017-04-18 |
MX2014005289A (es) | 2014-05-30 |
JP5976828B2 (ja) | 2016-08-24 |
US9115152B2 (en) | 2015-08-25 |
US20130116245A1 (en) | 2013-05-09 |
CN104024255A (zh) | 2014-09-03 |
WO2013067277A1 (en) | 2013-05-10 |
CL2014001158A1 (es) | 2014-09-12 |
AU2012332368A1 (en) | 2014-05-22 |
EP2773639B1 (en) | 2017-04-26 |
ZA201403158B (en) | 2017-09-27 |
IL232280A0 (en) | 2014-06-30 |
US20150094302A1 (en) | 2015-04-02 |
CN104024255B (zh) | 2017-01-18 |
KR20140090227A (ko) | 2014-07-16 |
CA2853970A1 (en) | 2013-05-10 |
US8729072B2 (en) | 2014-05-20 |
EP2773639A1 (en) | 2014-09-10 |
KR101716011B1 (ko) | 2017-03-13 |
JP2016028045A (ja) | 2016-02-25 |
TW201326171A (zh) | 2013-07-01 |
IN2014CN03265A (es) | 2015-07-03 |
US20140221365A1 (en) | 2014-08-07 |
AR088642A1 (es) | 2014-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20140187A (es) | Compuestos de piperazina alquilados como inhibidores de la actividad btk | |
UY39630A (es) | Inhibidores de bromodominios | |
DOP2015000158A (es) | Inhibidores de prmt5 y sus usos | |
CR20140194A (es) | Compuestos de heteroaril piridona y aza-piridona como inhibidores de la actividad btk | |
CU20140109A7 (es) | Compuestos heterocíclicos | |
CR20150119A (es) | Compuestos cíclicos éter pirazol-4-il-heterociclil-carboxamida y métodos de utilización | |
UY35663A (es) | Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos | |
CR20150045A (es) | Inhibidores de hepatitis c | |
CR11757A (es) | Compuestos de triazina como inhibidores mtor y quinasa pi3 | |
PH12015500064B1 (en) | Imidazotriazinecarbonitriles useful as kinase inhibitors | |
UY33536A (es) | INHIBIDORES BICÍCLICOS DE ACETIL-CoA-CARBOXILASA Y USOS DE LOS MISMOS | |
UY35675A (es) | Derivados sustituidos de quinazolin-4-ona | |
CO7030960A2 (es) | Inhibidores de pak para el tratamiento de los trastornos de proliferación celular | |
DOP2014000265A (es) | Novedosas n-piridinil amidas cíclicas sustituidas como inhibidores de quinasa | |
DOP2014000036A (es) | Compuestos de piridazinona y su uso como inhibidores daao | |
CO7131358A2 (es) | Compuestos de n-alquiltriazol como antagonistas de lpar | |
CU20150021A7 (es) | Piridinonas bicíclicas novedosas | |
GT201400131A (es) | Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina | |
UY33885A (es) | Inhibición de la il17 y del ifn-gamma para el tratamiento de las inflamaciones autoinmunes | |
CU20130139A7 (es) | Derivados glocósidos y usos de los mismos | |
CR20140516A (es) | Compuestos de pirazol sustituidos como antagonistas de lpar | |
UY34604A (es) | Inhibidores de oxadiazol de la producción de leucotrienos para terapia de combinación | |
UY34423A (es) | Nuevo procedimiento de síntesis de la ivabradina y de sus sales de adición a un ácido farmacéuticamente aceptable | |
UY34339A (es) | Inhibidores de la fosfatidilinositol 3-quinasa para el tratamiento del cancer | |
CR20150082A (es) | Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a |